[Neoadjuvant chemotherapy in non-small-cell lung cancer].

Abstract

Over the past 10 years, several studies of neoadjuvant chemotherapy for stage III Non Small Cell Lung Cancer (NSCLC) have been conducted. In eight Phase II studies, response rates of approximately 65% and resectability rates of approximately 50% have been achieved, with acceptable side effects. Two randomized trials with a total of 120 patients with stage… (More)

Topics

  • Presentations referencing similar topics